Low LDL cholesterol and increased risk of Parkinson's disease: Prospective results from Honolulu‐Asia Aging Study
暂无分享,去创建一个
Xuemei Huang | R. Mailman | Xuemei Huang | R. Abbott | H. Petrovitch | G. Ross | Robert D Abbott | G Webster Ross | Helen Petrovitch | Richard B Mailman | Richard B. Mailman | Xuemei Huang
[1] Y. Stern,et al. Pathological correlates of extrapyramidal signs in Alzheimer's disease , 1997, Annals of neurology.
[2] E. Parati,et al. Decreased cholesterol biosynthesis in fibroblasts from patients with Parkinson disease. , 1993, Biochemical medicine and metabolic biology.
[3] A. Jon Stoessl,et al. Etiology of Parkinson's Disease , 2003, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[4] Ward Cd,et al. Research diagnostic criteria for Parkinson's disease. , 1990 .
[5] H. Sagar,et al. A data‐driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes , 1999, Movement disorders : official journal of the Movement Disorder Society.
[6] C. Tanner,et al. Epidemiology of Parkinson's disease and akinetic syndromes , 2000, Current opinion in neurology.
[7] L. Heilbrun,et al. The origins of epidemiologic studies of heart disease, cancer and osteoporosis among Hawaii Japanese. , 1985, Hawaii medical journal.
[8] Lewis E Kazis,et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease , 2007, BMC medicine.
[9] Cecil M. Burchfiel,et al. Environmental, life-style, and physical precursors of clinical Parkinson’s disease: recent findings from the Honolulu-Asia Aging Study , 2003, Journal of Neurology.
[10] Anthony H V Schapira,et al. Etiology of Parkinson’s disease , 2006, Neurology.
[11] D.,et al. Regression Models and Life-Tables , 2022 .
[12] C. Tanner,et al. Frequency of bowel movements and the future risk of Parkinson’s disease , 2001, Neurology.
[13] M. Hernán,et al. Alcohol consumption and the incidence of Parkinson's disease , 2003, Annals of neurology.
[14] K. Jellinger. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms? , 1999, Journal of neural transmission. Supplementum.
[15] R. Mayeux,et al. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly , 1999, Neurology.
[16] Richard W. Murrow,et al. Lower low‐density lipoprotein cholesterol levels are associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[17] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[18] R. Worth,et al. Ascertainment of men of Japanese ancestry in Hawaii through World War II Selective Service registration. , 1970, Journal of chronic diseases.
[19] J. Jankovic,et al. Parkinson's Disease & Movement Disorders , 2002 .
[20] Daniel L. McGee,et al. Ten-year incidence of coronary heart disease in the Honolulu Heart Program. Relationship to biologic and lifestyle characteristics. , 1984, American journal of epidemiology.
[21] C. Tanner,et al. Association of coffee and caffeine intake with the risk of Parkinson disease. , 2000, JAMA.
[22] D. Morens,et al. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. , 1994, American journal of epidemiology.
[23] Nitin R. Patel,et al. Exact logistic regression: theory and examples. , 1995, Statistics in medicine.
[24] R. Kronmal,et al. The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.
[25] P. W. Lane,et al. Analysis of covariance and standardization as instances of prediction. , 1982, Biometrics.
[26] C. Poole,et al. APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. , 2004, Neurology.
[27] Beate Ritz,et al. Clinical characteristics in early Parkinson's disease in a central California population‐based study , 2005, Movement disorders : official journal of the Movement Disorder Society.
[28] S. Czuczwar,et al. Neuroprotective properties of statins. , 2005, Pharmacological reports : PR.
[29] Chris Zarow,et al. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. , 2003, Archives of neurology.
[30] P A Wolf,et al. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. , 1994, JAMA.
[31] Albert Hofman,et al. Serum cholesterol levels and the risk of Parkinson's disease. , 2006, American journal of epidemiology.
[32] J. Dallongeville,et al. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. , 1992, Journal of lipid research.
[33] E. Teng,et al. The Cognitive Abilities Screening Instrument (CASI): A Practical Test for Cross-Cultural Epidemiological Studies of Dementia , 1994, International Psychogeriatrics.
[34] C. Ward,et al. Research diagnostic criteria for Parkinson's disease. , 1990, Advances in neurology.
[35] D J Foley,et al. Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study. , 1996, JAMA.
[36] Chris Zarow,et al. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis , 2003, Neurobiology of Aging.
[37] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[38] C. Poole,et al. APOE-ϵ2 allele associated with higher prevalence of sporadic Parkinson disease , 2004 .
[39] J. Touchon,et al. Mild extrapyramidal signs and functional impairment in ageing , 2002, International journal of geriatric psychiatry.
[40] S. Fahn. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .
[41] R. Abbott. Logistic regression in survival analysis. , 1985, American journal of epidemiology.
[42] K. Yano,et al. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study , 2001, The Lancet.